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Background: From a health service perspective, society, with its limited resources, needs to be reassured that
evidence-based medicine is also effective when carried out in the frame of ordinary clinical practice. The
effectiveness of rehabilitation programs in ankylosing spondylitis (AS) has been proven to be effective in clinical
trials. However, less is known when this is carried out in clinical practice. The aim of this study was to evaluate the
effect of a 2-weeks rehabilitation program on self-reported outcome and physical function in patients with axial
spondyloarthritis (ax-SpA) including AS patients carried out in ordinary clinical practice. The program contained of
daily water exercises, exercises for flexibility, muscle strength, and cardio-respiratory fitness.
Results: A total of 87 ax-SpA patients (60 men, 27 women), aged ≥ 18 years were identified to have participated in
the 2-weeks in-patient rehabilitation program. Mean age was 49 years and disease duration was 14 years. 92.5%
were HLA-B27 positive, 62% were current users of non-steroidal anti-inflammatory drugs, and 17% were current
users of tumour necrosis factor inhibitors. After 2-weeks, a statistical significant improvement (p < 0.001) was
observed for patient-reported outcomes (Bath Ankylosing Spondylitis (BAS) Disease Activity Index 4.3 vs. 3.1, BAS
Functional Index 3.1 vs. 2.4) and physical measured outcomes (BAS Metrology Index 3.23 vs. 2.29, Gait Velocity 2.2
vs. 2.6 m/s, timed-stands test 22.5 vs. 16.3 s, finger-floor distance 17.9 vs. 8.9 cm, chest expansion 3.9 vs. 4.6 cm).
Conclusion: Data, from our retrospective case series report, support that patient with ax-SpA benefit from short-
term rehabilitation when it is carried out in ordinary clinical care. Data from ordinary clinical care may be important
when discussing the effectiveness of a treatment and allocating resources in the health care system.
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Axial Spondyloarthritis (ax-SpA) is diagnosed when
signs and symptoms caused by chronic inflammation in
the axial skeleton is present. Inflammation in the axial
skeleton causes pain, stiffness and limitation of thoracic
and spinal mobility. The imaging hallmark of ax-SpA is
sacroiliitis visible, e.g. on radiographs or magnetic reson-
ance imaging (MRI) and signs of new bone formations
in the axial skeleton [1]. Ankylosing spondylitis (AS) is a
phenotype of ax-SpA, diagnosed by the presence of
sacroiliitis on radiographs, which in its final stage may* Correspondence: glenn.haugeberg@sshf.no
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reproduction in any medium, provided the orcause ankylosing at sacroiliac joints and the spine [2].
Apart from pharmacological treatment (Non Steroidal
Anti-Inflammatory Drugs (NSAIDs) and anti-Tumour
Necrosis Factor (TNF) -α treatment), exercise and re-
habilitation therapy are cornerstones in the management
of ax-SpA including AS [3,4].
There is a substantial body of evidence in the literature
proving that various spa and exercise programs tested in
randomised trials have a beneficial effect in AS patients
improving physical function and reducing symptoms of
disease [5-12]. In a recent review, the authors concluded
that physical therapy exercises in various modalities have
positive effects on BASFI, BASDAI, pain and mobility
outcomes [13]. Furthermore, in a Cochrane review, the
results suggested individual home-based or supervised
exercise programs to be better than non-intervention,ral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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exercise, and combined in-patient spa-exercise therapy
followed by group physiotherapy to be better than group
physiotherapy alone [14]. This knowledge is reflected in
recommendations for management of AS, highlighting
that regular exercise and rehabilitation therapy are part
of the treatment strategy [3,15].
The gold standard for treatment in modern medicine
is based on evidence from randomised clinical trials.
However, the knowledge on the benefit and effect of a
treatment and/or an intervention carried out in daily
clinical care is also important and essential for patients,
health care providers and decision makers in the health
care system [16,17]. This can reassure that treatment
based on evidence is also effective when applied in daily
clinical practice.
The main aim of this study was to evaluate the short-
term effect of an in-patient 2-weeks rehabilitation and
exercise program on self-reported outcome and physical
functions in ax-SpA patients, within the frame of stand-
ard routine and clinical care.
Methods
In this retrospective case series report we retrieved from
our hospital database ax-SpA patients who had partici-
pated in our 2-weeks in-patient rehabilitation intervention
program in the period from January 2007 to June 2011.
The Department of Rheumatology is the only one of its
kind located in the geographic area of southern NorwayTable 1 Patient-reported outcome measures (PROMs), therap
spondyloarthritis patients following a 2-weeks in-patient reh
N* Ba
PROMs
BASDAI, 0–10 scale 59 4.3
BASFI, 0–10 scale 57 3.1
Therapist measured outcomes
BASMI, 0–10 scale 87 3.2
Gait velocity, m/s 83 2.2
Timed-stand test, s 86 21
Finger-to-floor distance, cm 49 15
11
Chest expansion, cm 46 3.7
Laboratory data
ESR, mm/hr 32 22
14
CRP, mg/l 47 10
5.0
Data are presented as mean with (standard deviation) and also with median [inter-
* Values differ from 87 due to missing values.
** Paired student’s t-test comparing mean values and Wilcoxon test comparing med
BASDAI: Bath Ankylosing Spondylitis Disease Activity Index, BASFI: Bath Ankylosing
Index, ESR: Erythrocyte Sedimentation Rate. CRP: C-reactive protein.with a population of approximately 200 000 inhabitants,
aged 20 years and older. All included patients had to
be ≥18 years of age and have a diagnosis of ax-SpA with
imaging findings on X-ray, computer tomography (CT)
and/or MRI confirming sacroiliitis.
All ax-SpA patients who were participating had been re-
ferred by a rheumatologist. Only patients thought to bene-
fit from the program based on an overall clinical judgment
were included in the program. Patients with severe
comorbidities or severe reduced exercise tolerance were
not offered participation in the program. All patients had
signs and symptoms from their ax-SpA. The patients were
assessed at admission and at the end of the 2-weeks pro-
gram, following a standard clinical procedure for clinical
assessment of ax-SpA patients at the department, which
included both patient-reported outcome measures and
therapist-measured outcomes. Standard routine clinical
data collection and registration at the department included
a broad spectre of demographics, measures of disease ac-
tivity, health status and physical function, laboratory data
and treatment (Table 1). Disease activity was assessed by
Bath Ankylosing Disease Activity Index (BASDAI) which
consists of six visual analogue scales dealing with fatigue,
spinal pain, joint pain, localised tenderness, and quality
and quantity of morning stiffness [18]. Functional status
was evaluated by Bath Ankylosing Functional Index
(BASFI) which consists of eight visual analogue scales deal-
ing with physical function and two scales reflecting the pa-
tient’s ability to cope with daily activities [19]. Bathist measured outcomes and laboratory data in axial
abilitation and training program
seline 2-weeks follow-up P**
(2.2) 3.1 (2.1) <0.001
(1.9) 2.3 (2.0) <0.001
(2.4) 2.3 (2.4) <0.001
(0.5) 2.7 (0.6) <0.001
.8 (8.1) 15.8 (4.8) <0.001
.1 (14.0) 9.1 (12.7) <0.001
.0 [25.0] 0 [16.0] <0.001
(2.2) 4.7 (2.3) <0.001
.6 (23.4) 18.7 (15.3) 0.21
.0 [17.0] 16.0 [22.8] 0.44
.3 (13.7) 9.3 (10.7) 0.59
[7.1] 4.4 [15.6] 0.71
quartile range] when data distribution were skewed.
ian values.
Spondylitis Functional Index, BASMI: Bath Ankylosing Spondylitis Metrology
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the measurements of wall-to-tragus distance, lumbar
flexion, cervical rotation, lumbar lateral flexion, and
intermalleolar distance [20]. These measurements are
widely used instruments in assessment of patients suffering
from ax-SpA. A flexible measuring tape was used to meas-
ure mobility variables: chest expansion and finger-to-floor
distance. Standardised registration in this program also in-
cluded two generic instruments for physical function, the
timed-stands test which measures ten repetitions sit-to
-stand [21], and a 6 m maximum gait velocity test. The
same physiotherapist examined the patient at admission
and at discharge and performed all therapist-measured
outcomes.
The multidisciplinary team at the rehabilitation unit
consists of rheumatologist, physiotherapist, occupational
therapist, social worker, and secretary. The training pro-
gram, which was performed 5 days a week, was organised
by an experienced physiotherapist and based on current
evidence-based knowledge. The daily rehabilitation pro-
gram consists of water exercises (30 minutes), basic exer-
cises for movement, muscle strength and stability, balance
and coordination (45 minutes), and exercises for endur-
ance (40 minutes), aiming at keeping the training intensity
as recommended in the literature [22]. The training is
instructed by a physiotherapist in groups of four, but with
an individual focus according to the individual goals and
statuses of the patients. In addition, every patient has daily
individual physiotherapy including massage, stretching,
mobilisation/articulation and advice on specific exercises
to enhance a good body posture. The patients were also
followed up as needed by the other professions listed
above.
We also aimed to collect data on BASDAI, BASFI and
BASMI from the first follow-up at the outpatient clinic
after the training program. These data were collected as
part of a clinical visit at the rheumatology out-patient
clinic were retrieved from the hospital database.
We used the SPSS statistical program, version 16.0 to do
the statistical analysis. Normal distributed data were
presented as mean with standard deviation (SD) and data
with skewed distribution were also presented as median
with inter-quartile range (25th–75th percentiles).
For group comparison, we used paired Student’s t-test
for continuous variables. If continuous variables had a
skewed distribution, we also performed a non-parametric
Wilcoxon test. For variables with a statistically significant
difference between baseline and 2 weeks follow-up, the
change from baseline to 2 weeks was also presented as a
percentage change with 95% confidence intervals (CI).
The physiotherapist involved in patient assessment (SGE)
did not analyse the data.
The study was approved by the regional committee for
ethics and medical research (REK sør-øst, Norway).Results
For the assessment period 95 ax-SpA patients started
the 2-week rehabilitation program. Among them 8 pa-
tients (6 men and 2 women) did not complete the
2-week program for various reasons including acute
infectious diseases, acute low back pain, depression and
vertigo. A total of 87 ax-SpA patients were thus eligible
for evaluation (60 men and 27 women). Mean (SD) age
was 49.2 (10.0) years, body mass index (BMI) was
26.7 kg/m2 (3.5), education was 12.2 (4.0) years, and dis-
ease duration was 14.4 years (11.9). Among the patients,
92.5% were HLA-B27 positive and 27.2% were smoking.
Furthermore, 50.6% were employed, 9.2% had combined
disability pension and were employed part-time and
29.9% had a disability pension. Among the patients,
62.1% were current users of NSAIDs and 17.2% of
TNF inhibitors (10 etanercept, 3 infliximab and 2
adalimumab). All patients fulfilled the Assessment of
SpondyloArthritis international Society (ASAS) criteria
for axial spondyloarthritis [1]. All patients had imaging
evidence of sacroiliitis. Among the 72 patients with
available radiographs of the sacroiliac joint 64 patients
had radiographic sacroiliitis and fulfilled the modified
New York criteria for AS [2]. Among the 23 patients not
fulfilling the New York criteria for AS, 18 patients had
sacroiliitis on MRI and 5 patients had sacroiliitis on CT.
As shown in Table 1, a statistical significant improve-
ment (p < 0.001) was observed both for patient-reported
and physical-measured outcomes after 2 weeks. Ex-
pressed as percentages (95% CI), the improvement for
mean BASDAI was 27% (18–37%), for BASFI 26% (15–
37%), for BASMI 29% (22–36%), for gait velocity 20%
(17–23%), for timed-stand test 27% (23–32%), for finger-
to-floor distance 40% (26–53%) and chest expansion
26% (19–33%). However, no significant differences were
seen for ESR (16.5 vs. 16.9 mm/hr) and CRP (8.2 vs.
8.3 mg/l).
Among the 48 ax-SpA patients with retrievable follow-
up data, no significant differences were seen in a mean
time-period of 9.3 months (SD 6.9) after the training
program for BASDAI [mean 4.4 (2.2) vs 4.1 (2.3), p =
0.24] and BASFI [mean 3.5 (2.6) vs 3.2 (2.0), p = 0.31].
However, BASMI at follow-up remained significantly im-
proved, compared with the baseline [mean 2.7 (2.5) vs
3.3 (2.6), p = 0.02].Discussion
Our study supports that patients with ax-SpA, benefit
from structured and intensive exercise training pro-
grams, and also when these are carried out in the setting
of ordinary clinical practice. In our study, ax-SpA
patients improved self-reported disease activity by 27%
(BASDAI) and function by 26% (BASFI), whereas
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20% for gait velocity to 40% for finger-to-floor distance.
Various exercise and rehabilitation programs proving ef-
ficacy have been tested in randomised trials [5-12]. This
includes different exercise programs [9,10,12], spa re-
habilitation and exercise programs [6,7], combined inten-
sive group exercise with an educational-behavioural
program [8], and rehabilitation and exercise programs
tested in different climates [11]. In a Cochrane review of
the literature, it was concluded that supervised group
therapy was better than home exercises, and combined in-
patient spa-exercise therapy followed by group physiother-
apy was better than group physiotherapy alone [14]. In
our study, exercises were carried out in groups.
In the study by Strumse et al., comparing a 4-weeks
rehabilitation program in Mediterranean and Norwegian
settings [11], patients in the Norwegian environment re-
duced their BASDAI by 1.9 from a baseline of 5.8 (33%)
and BASFI by 1.2 from a baseline of 4.3 (28%) which is
in the same percentage range as in our study. Patients,
however, in the Mediterranean setting had a significantly
higher reduction than for patients in the Norwegian set-
ting with a reduction in BASDAI by 4.2 from a baseline
of 6.2 (68%) and BASFI by 2.6 from a baseline of 4.3
(60%). The results of this study indicate that warm cli-
mate does have an additional effect on rehabilitation and
exercise programs for the AS patients. The baseline
values in this study were, however, higher than in our
study.
Pharmacological treatment with NSAIDs [23] and TNF
inhibitors [24-26] has proven to improve signs and symp-
toms and to improve physical function in AS. NSAIDs are
considered as first-line in pharmacological treatment of
AS, whereas, TNF inhibitors are recommended used in
patients with active disease when exercise, and physiother-
apy and NSAIDs have failed [3]. In our study, 62% were
NSAID and 17% were current users of TNF inhibitors. In
the ASSERT-infliximab study, evaluating the efficacy of
infliximab in AS patients with active disease at inclusion
(BASDAI ≥ 4), patients improved in median their BASDAI
by 2.9, BASFI by 1.7 and BASMI by 1.0 scale points during
24 weeks of follow up, reflecting a percentage improve-
ment by, approximately, 45% for BASDAI, 30% for BASFI
and 21% for BASMI [24]. The same level of improvement
rates has also been reported for other TNF inhibitors, e.g.
adalimumab and etanercept [25,26]. Interestingly, the cor-
responding figures for percentage changes for BASDAI,
BASFI and BASMI in our study were in the same range as
for these studies exploring the effect of TNF inhibition.
This emphasises and illustrates the effectiveness of exer-
cise programs in AS patients.
In the randomised, controlled study by Masiero et al.,
was demonstrated that even AS patients stabilised on TNF
inhibitors were able to further improve spine mobility andreduce pain, stiffness, and disability by a rehabilitation pro-
gram based on an educational-behavioral intervention and
exercise training program [8]. In the study by Colina et al.,
an intensive rehabilitation program in AS patients treated
with the TNF-inhibitor etanercept was shown to contribute
to reducing disability and to ameliorating quality of life [6].
These points highlight that exercise programs should be
part of the treatment strategy, even in patients who have
responded favourably to anti-TNF treatment. The import-
ance of exercise programs in AS is further highlighted by
evidence suggesting that AS patients are at increased risk of
cardiovascular diseases [27]. In a recently published cross-
sectional study, AS patients were found not only to have re-
duced flexibility, but also to have lower cardio-respiratory
fitness, again underlining the importance of exercising in
this patient group [28].
Exercise programs have also been proven to be cost
effective. A randomised controlled trial showed that com-
bined spa-exercise therapy with drugs and weekly group
physical therapy had a more favourable cost-effectiveness
and cost-utility compared with patients who stayed at
home and continued their usual activities and standard
treatment [29].
One of the big challenges is patient’s adherence to the
exercise program [30]. In a recent publication, evaluating
exercise programs, it was found that only four trials
reported on participants’ adherence to the exercise pro-
grams and that only one provided sufficient information
to evaluate the possible influence of the adherence [30].
Our data indicate that the positive effects on self-
reported disease activity (BASDAI) and function (BASFI)
gained from the training program are lost and dimin-
ished after the training program is stopped. In a recently
published prospective Norwegian study, it was found
that patients were back to their base-line health status
six months after discharge from rehabilitation [12]. This
highlights the importance of supporting patients and en-
couraging them to continue exercising and also, after
finishing intensive exercise programs, to maintain the
levels of benefits that have been achieved.
One of the major challenges comparing the results be-
tween rehabilitation studies is the lack of standardisation
and the variation in the content, exercise intensity and
duration. In our study, the intervention period was 5 days
a week for 2 weeks, whereas, e.g. in the study by Colina
et al., [6] the intervention period was one week and in
the study by Ince et al., the period was three months
[10]. In our study, the daily program consisted of water
exercises (30 minutes), basic exercises for movement,
muscle strength and stability, balance and coordination
(45 minutes), and exercises for endurance (40 minutes).
In addition, every patient had daily individual physio-
therapy including massage, stretching, mobilisation and
articulation, and advice on specific exercises to enhance
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ercise program consisted of 50 minutes of multimodal
exercise, including aerobic, stretching, and pulmonary
exercises, 3 times a week for 3 months [10]. Whereas, in
the study by Masiero et al., the program consisted of 12
rehabilitation exercise sessions (stretching, strengthen-
ing, chest and spine/hip joint flexibility exercises), which
patients performed at home [8].
The limitations of our study include both selection bias
of participants and study design. The study design was
retrospective, based on data collection as part of clinical
routine. Despite the clinical nature of this program and
registration of variables which were standardised, data
were missing in a high proportion of patients, particularly
for some variables (e.g. BASDAI and BASFI). This empha-
sises that there is a need for more attention and focus, in
clinical practice, to use recommended outcome measures
in the follow-up and assessment of patients with inflam-
matory rheumatic disorders. In the updated 2010 ASAS/
EULAR recommendations for the management of AS, dis-
ease monitoring of patients with AS is recommended to
include data on e.g. patient history (e.g. questionnaires),
clinical parameters and laboratory tests [15]. Our experi-
ence demonstrates that disease monitoring in clinical
practice is facilitated and has improved in our hospital
after we started to use the GoTreatIT-rheumaW computer
system (www.diagraphit.com), designed to monitor pa-
tients, in daily clinical practice, with inflammatory joint
disorders [31]. Furthermore, the ax-SpA patients we
assessed were not a random selection of the ax-SpA popu-
lation, followed in our out-patient clinic. Patients who did
not have e.g. sufficient effect of medical treatment were
more likely recruited. Another limitation, was the inclu-
sion criteria which was only based on an overall judge-
ment by the referral rheumatologist, that the patients were
thought to benefit from this program. The lack of a con-
trol group also limits the scientific validity of the data, as
the placebo effect was not controlled for and further in-
cludes both patient-reported outcome measures and
therapist-measured outcomes. Another limitation of this
study is that no intra-rater reliability tests were performed
for the measurements used. However, for the metric meas-
urement, BASMI, and for the patient reported outcome
measures, BASDAI and BASFI, the instruments have been
shown to be reliable, valid and sensitive to change [20,32].
The strength of our study is that data have been cap-
tured from real life and based on how the ax-SpA patients
have been handled in ordinary clinical practice. Thus, the
design of this study enables us to test evidence-based
treatment recommendations [14] and to validate if the ef-
fect of rehabilitation can also be demonstrated in clinical
practice, after demonstration in clinical trials. Our data
add evidence that organised and structured physiotherapy
is of benefit for the ax-SpA patients. Probably, it has alsobeen of advantage that all measures of physical function
were performed by experienced physiotherapists, thus, re-
ducing the risk of measurement errors.
Interestingly, our data indicate that the positive effect
on BASMI, which is a composite physical measure of
physical function, is also maintained after weeks and
months after the training program is stopped. This posi-
tive findings should be interpreted with caution, as the
follow-up measures of function for BASMI were not
performed by the same assessor as during the 2-weeks
training program.
Conclusion
Data from our retrospective case series report, support
that patients with ax-SpA, benefit from short-term re-
habilitation when carried out in ordinary clinical care.
From a health service perspective “reality-based studies”
are important when discussing the effectiveness of a
treatment and allocating resources in the health care
system.
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